TABLE 3.
Antifungal sensitivity of biofilms of three C. albicans clinical isolates from early failing VPs.
| Antifungal |
C. albicans G-3065 |
C. albicans G-8424 |
C. albicans G-1625 |
|||
| 0.03% CO2 | 5% CO2 | 0.03% CO2 | 5% CO2 | 0.03% CO2 | 5% CO2 | |
| Fluconazole | ||||||
| 32 μg/ml | + | + | ++ | − | +++ | ++ |
| 128 μg/ml | + | + | +++ | − | +++ | ++ |
| Miconazole | ||||||
| 32 μg/ml | − | − | − | − | − | + |
| 128 μg/ml | ++ | − | +++ | − | +++ | + |
| Nystatin | ||||||
| 2 μg/ml | +++ | +++ | − | + | + | + |
| 8 μg/ml | +++ | +++ | ++ | +++ | +++ | +++ |
Action of antifungals was measured via the XTT assay activity relative to untreated in both 0.03 and 5% CO2: − >80%, + 60–80%, ++ 40–60%, +++ <40%.